Liver Cancer

Merck to pay $3.85B for hepatitis C drug developer

Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies ...

Jun 09, 2014
popularity not rated yet | comments 0

Liver cancer vaccine effective in mice

Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.

Jun 03, 2014
popularity 5 / 5 (3) | comments 0

Latest Spotlight News